Selected research
Industry Growth & Trends
Global Oral Mesalazine Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Oral Mesalazine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Oral Mesalazine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Oral Mesalazine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Oral Mesalazine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Oral Mesalazine market include Teva Pharmaceutical Industries, Ferring Global, AbbVie, Tillotts Pharma, Shire, Salix Pharmaceuticals, Nogra Pharma Limited, Morningside Healthcare and Dr. Falk Pharma UK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Oral Mesalazine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Oral Mesalazine market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oral Mesalazine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oral Mesalazine.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Oral Mesalazine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Oral Mesalazine Market by Company
Teva Pharmaceutical Industries
Ferring Global
AbbVie
Tillotts Pharma
Shire
Salix Pharmaceuticals
Nogra Pharma Limited
Morningside Healthcare
Dr. Falk Pharma UK
Oral Mesalazine Segment by Type
Capsules
Granule
Tablets
Oral Mesalazine Segment by Application
Inflammatory Bowel Disease
Ulcerative Colitis
Crohn's Disease
Others
Oral Mesalazine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Mesalazine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Mesalazine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Mesalazine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Oral Mesalazine companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Capsules
- Granule
- Tablets
Applications
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Crohn's Disease
- Others
Companies covered
- Teva Pharmaceutical Industries
- Ferring Global
- AbbVie
- Tillotts Pharma
- Shire
- Salix Pharmaceuticals
- Nogra Pharma Limited
- Morningside Healthcare
- Dr. Falk Pharma UK
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Oral Mesalazine Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Oral Mesalazine Market Size by Region (2021-2032)
- 1.4.1 Global Oral Mesalazine Market Size by Region (2021-2026)
- 1.4.2 Global Oral Mesalazine Market Size by Region (2027-2032)
- 1.5 Key Regions Oral Mesalazine Market Size (2021-2032)
- 1.5.1 North America Oral Mesalazine Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Oral Mesalazine Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Oral Mesalazine Market Size Growth Rate (2021-2032)
- 1.5.4 South America Oral Mesalazine Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Oral Mesalazine Market Size Growth Rate (2021-2032)
2 Oral Mesalazine Market by Type
- 2.1 Type Introduction
- 2.1.1 Capsules
- 2.1.2 Granule
- 2.1.3 Tablets
- 2.2 Global Oral Mesalazine Market Size by Type
- 2.2.1 Global Oral Mesalazine Market Size Overview by Type (2021-2032)
- 2.2.2 Global Oral Mesalazine Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Oral Mesalazine Market Size Forecasted by Type (2027-2032)
- 2.3 Global Oral Mesalazine Market Size by Regions
- 2.3.1 North America Oral Mesalazine Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Oral Mesalazine Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Oral Mesalazine Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Oral Mesalazine Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Oral Mesalazine Market Size Breakdown by Type (2021-2026)
3 Oral Mesalazine Market by Application
- 3.1 Type Introduction
- 3.1.1 Inflammatory Bowel Disease
- 3.1.2 Ulcerative Colitis
- 3.1.3 Crohn's Disease
- 3.1.4 Others
- 3.2 Global Oral Mesalazine Market Size by Application
- 3.2.1 Global Oral Mesalazine Market Size Overview by Application (2021-2032)
- 3.2.2 Global Oral Mesalazine Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Oral Mesalazine Market Size Forecasted by Application (2027-2032)
- 3.3 Global Oral Mesalazine Market Size by Regions
- 3.3.1 North America Oral Mesalazine Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Oral Mesalazine Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Oral Mesalazine Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Oral Mesalazine Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Oral Mesalazine Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Oral Mesalazine Industry Trends
- 4.2 Oral Mesalazine Industry Drivers
- 4.3 Oral Mesalazine Industry Opportunities and Challenges
- 4.4 Oral Mesalazine Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Oral Mesalazine Revenue (2021-2026)
- 5.2 Global Oral Mesalazine Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Oral Mesalazine Key Company Headquarters & Area Served
- 5.4 Global Oral Mesalazine Company, Product Type & Application
- 5.5 Global Oral Mesalazine Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Oral Mesalazine Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Oral Mesalazine Players Market Share by Revenue in 2025
- 5.6.3 2025 Oral Mesalazine Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva Pharmaceutical Industries
- 6.1.1 Teva Pharmaceutical Industries Company Information
- 6.1.2 Teva Pharmaceutical Industries Business Overview
- 6.1.3 Teva Pharmaceutical Industries Oral Mesalazine Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva Pharmaceutical Industries Oral Mesalazine Product Portfolio
- 6.1.5 Teva Pharmaceutical Industries Recent Developments
- 6.2 Ferring Global
- 6.2.1 Ferring Global Company Information
- 6.2.2 Ferring Global Business Overview
- 6.2.3 Ferring Global Oral Mesalazine Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Ferring Global Oral Mesalazine Product Portfolio
- 6.2.5 Ferring Global Recent Developments
- 6.3 AbbVie
- 6.3.1 AbbVie Company Information
- 6.3.2 AbbVie Business Overview
- 6.3.3 AbbVie Oral Mesalazine Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 AbbVie Oral Mesalazine Product Portfolio
- 6.3.5 AbbVie Recent Developments
- 6.4 Tillotts Pharma
- 6.4.1 Tillotts Pharma Company Information
- 6.4.2 Tillotts Pharma Business Overview
- 6.4.3 Tillotts Pharma Oral Mesalazine Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Tillotts Pharma Oral Mesalazine Product Portfolio
- 6.4.5 Tillotts Pharma Recent Developments
- 6.5 Shire
- 6.5.1 Shire Company Information
- 6.5.2 Shire Business Overview
- 6.5.3 Shire Oral Mesalazine Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Shire Oral Mesalazine Product Portfolio
- 6.5.5 Shire Recent Developments
- 6.6 Salix Pharmaceuticals
- 6.6.1 Salix Pharmaceuticals Company Information
- 6.6.2 Salix Pharmaceuticals Business Overview
- 6.6.3 Salix Pharmaceuticals Oral Mesalazine Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Salix Pharmaceuticals Oral Mesalazine Product Portfolio
- 6.6.5 Salix Pharmaceuticals Recent Developments
- 6.7 Nogra Pharma Limited
- 6.7.1 Nogra Pharma Limited Company Information
- 6.7.2 Nogra Pharma Limited Business Overview
- 6.7.3 Nogra Pharma Limited Oral Mesalazine Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Nogra Pharma Limited Oral Mesalazine Product Portfolio
- 6.7.5 Nogra Pharma Limited Recent Developments
- 6.8 Morningside Healthcare
- 6.8.1 Morningside Healthcare Company Information
- 6.8.2 Morningside Healthcare Business Overview
- 6.8.3 Morningside Healthcare Oral Mesalazine Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Morningside Healthcare Oral Mesalazine Product Portfolio
- 6.8.5 Morningside Healthcare Recent Developments
- 6.9 Dr. Falk Pharma UK
- 6.9.1 Dr. Falk Pharma UK Company Information
- 6.9.2 Dr. Falk Pharma UK Business Overview
- 6.9.3 Dr. Falk Pharma UK Oral Mesalazine Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Dr. Falk Pharma UK Oral Mesalazine Product Portfolio
- 6.9.5 Dr. Falk Pharma UK Recent Developments
7 North America
- 7.1 North America Oral Mesalazine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Oral Mesalazine Market Size by Country (2021-2026)
- 7.3 North America Oral Mesalazine Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Oral Mesalazine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Oral Mesalazine Market Size by Country (2021-2026)
- 8.3 Europe Oral Mesalazine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Oral Mesalazine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Oral Mesalazine Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Oral Mesalazine Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Oral Mesalazine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Oral Mesalazine Market Size by Country (2021-2026)
- 10.3 South America Oral Mesalazine Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Oral Mesalazine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Oral Mesalazine Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Oral Mesalazine Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst